魏氏二步七法治疗腰椎间盘突出症的生物力学机制及疗效评价研究

注册号:

Registration number:

ITMCTR2200005733

最近更新日期:

Date of Last Refreshed on:

2022-03-16

注册时间:

Date of Registration:

2022-03-16

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

魏氏二步七法治疗腰椎间盘突出症的生物力学机制及疗效评价研究

Public title:

Study on biomechanical mechanism and efficacy evaluation of Wei's two-step seven method for treatment of lumbar disc herniation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

魏氏二步七法治疗腰椎间盘突出症的生物力学机制及疗效评价研究

Scientific title:

Study on biomechanical mechanism and efficacy evaluation of Wei's two-step seven method for treatment of lumbar disc herniation

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200057761 ; ChiMCTR2200005733

申请注册联系人:

薛彬

研究负责人:

薛彬

Applicant:

xuebin

Study leader:

xuebin

申请注册联系人电话:

Applicant telephone:

18817821387

研究负责人电话:

Study leader's telephone:

18817821387

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

skxuebin@163.com

研究负责人电子邮件:

Study leader's E-mail:

skxuebin@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市黄浦区瑞金二路197号2号楼2楼

研究负责人通讯地址:

上海市黄浦区瑞金二路197号2号楼2楼

Applicant address:

197 Second Ruijin Road, Huangpu District, Shanghai, China

Study leader's address:

197 Second Ruijin Road, Huangpu District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

skxuebin@163.com

研究负责人邮政编码:

Study leader's postcode:

200025

申请人所在单位:

上海交通大学医学院附属瑞金医院

Applicant's institution:

The Ruijin Hospital Afiliated to Shanghai Jiao Tong University School of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2021)临伦审第(414)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海交通大学医学院附属瑞金医院伦理委员会

Name of the ethic committee:

Ethics Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/1/27 0:00:00

伦理委员会联系人:

王译锋

Contact Name of the ethic committee:

王译锋

伦理委员会联系地址:

上海市黄浦区瑞金二路197号

Contact Address of the ethic committee:

197 Second Ruijin Road, Huangpu District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属瑞金医院

Primary sponsor:

The Ruijin Hospital Afiliated to Shanghai Jiao Tong University School of Medicine

研究实施负责(组长)单位地址:

上海市黄浦区瑞金二路197号

Primary sponsor's address:

197 Second Ruijin Road, Huangpu District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

上海市

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属瑞金医院

具体地址:

上海市黄浦区瑞金二路197号

Institution
hospital:

The Ruijin Hospital Afiliated to Shanghai Jiao Tong University School of Medicine

Address:

197 Second Ruijin Road, Huangpu District

经费或物资来源:

上海市青年科技英才扬帆计划项目

Source(s) of funding:

Sponsored by Shanghai Sailing Program

研究疾病:

腰椎间盘突出症

研究疾病代码:

Target disease:

Lumbar disc herniation

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

主要目的:基于中医“筋骨评估”理论,借助于现代医疗评价设 备,开展魏氏二步七法的临床疗效再评价;立足于现代生物力学 技术前沿,阐述魏氏伤科二步七法治疗腰椎间盘突出症的生物力学机制。 次要目的:将魏氏伤科特色诊疗技术与现代生物力学技术相结合,探索客观准确的腰椎间盘突出诊疗评价体系。

Objectives of Study:

Main objectives: Based on the theory of "bone and muscle assessment" in Traditional Chinese medicine, with the help of modern medical evaluation equipment, to carry out the reevaluation of the clinical efficacy of Wei's two-step seven manipulation; Based on the modern biomechanical technology, the biomechanical mechanism of the treatment of lumbar intervertebral disc herniation by two steps and seven methods of Wei's department of Traumatology was expounded. Secondary objective: To explore an objective and accurate diagnosis and treatment evaluation system for lumbar disc herniation by combining the characteristic diagnosis and treatment technology of Wei's department of Traumatology with modern biomechanical technology.

药物成份或治疗方案详述:

干预治疗方案:魏氏二步七法 干预治疗时间:每周治疗 3 次,4 周为一疗程。 魏氏二步七法具体操作步骤:俯卧位点揉法、腰部提拉法、弹拨按揉法、提腿 点揉法、牵引抖腰法、推扣腰背法、仰卧位悬足压膝法。

Description for medicine or protocol of treatment in detail:

Intervention method: Wei's two-step seven manipulation Intervention time: 3 times a week, 4 weeks as a course of treatment. Wei's two-step seven manipulation operation steps: prone site kneading method, waist lifting method, plucked by kneading method, lifting leg point kneading method, traction shake waist method, push buckle waist back method, supine suspension knee method.

纳入标准:

1)符合诊断标准,包括临床体征和影像学资料,其中中医诊断标准:参照《中医病证诊断疗效标准》中 LDH 的诊断标准;西医诊断标准:参照《腰椎间盘突出症诊疗中国疼痛专家共识》的相关内容。 2)签署带日期的知情同意书,承诺遵守研究程序,并配合实施全过程研究。 3)年龄为 18-65 岁。 4)同意接受治疗并签署知情同意书。

Inclusion criteria

1) Meet the diagnostic criteria, including clinical signs and imaging data, among which the diagnostic criteria of TCM: refer to the diagnostic criteria of LDH in the Diagnostic and Therapeutic Criteria of TCM Diseases and Syndromes; Western diagnostic criteria: refer to the relevant content of the Chinese expert consensus on the diagnosis and treatment of lumbar disc herniation. 2) Sign informed consent with date, promise to abide by the study procedure, and cooperate with the implementation of the whole process of the study. 3) Aged 18-65. 4) Agree to receive treatment and sign informed consent.

排除标准:

1)不能配合完成资料收集者或资料不全者; 2)合并腰椎骨折,或有结核、肿瘤等局部骨病患者; 3)合并有心血管、肝肾或造血系统等严重原发性疾患者,有其他自身免疫性疾病、变态反应性疾病和急、慢性感染者; 4)精神病患者,或有严重更年期症状的女性患者; 5)妊娠期或哺乳期妇女; 6)2 周内正在进行其他本疾病疗法的实验研究。

Exclusion criteria:

1) Unable to cooperate with the completion of data collection or incomplete data; 2) Patients with lumbar vertebrae fracture or local bone diseases such as tuberculosis and tumor; 3) Patients with serious primary diseases such as cardiovascular, liver, kidney or hematopoietic system, other autoimmune diseases, allergic diseases and acute or chronic infected persons; 4) Psychiatric patients, or women with severe menopausal symptoms; 5) Pregnant or lactating women; 6) Experimental studies of other therapies for this disease are under way within 2 weeks.

研究实施时间:

Study execute time:

From 2022-01-01

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2022-03-17

To      2022-12-01

干预措施:

Interventions:

组别:

治疗组

样本量:

33

Group:

treatment group

Sample size:

干预措施:

魏氏二步七法

干预措施代码:

Intervention:

Wei's two-step seven manipulation

Intervention code:

组别:

对照组

样本量:

33

Group:

control group

Sample size:

干预措施:

传统推拿手法

干预措施代码:

Intervention:

Traditional massage techniques

Intervention code:

样本总量 Total sample size : 66

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

上海市

Country:

china

Province:

Shanghai

City:

上海市

单位(医院):

上海交通大学医学院附属瑞金医院

单位级别:

三级甲等

Institution/hospital:

The Ruijin Hospital Afiliated to Shanghai Jiao Tong University School of Medicine

Level of the institution:

测量指标:

Outcomes:

指标中文名:

近红外脑功能检查评估

指标类型:

主要指标

Outcome:

/

Type:

Primary indicator

测量时间点:

治疗前及治疗1个疗程后

测量方法:

近红外脑功能成像系统

Measure time point of outcome:

Before treatment and after one course of treatment

Measure method:

Near-infrared functional brain imaging system

指标中文名:

Oswestry 指数评定

指标类型:

主要指标

Outcome:

/

Type:

Primary indicator

测量时间点:

治疗前、治疗10天、治疗20天、治疗1个疗程后

测量方法:

Oswestry 指数评定量表

Measure time point of outcome:

Before treatment, 10 days of treatment, 20 days of treatment, 1 course of treatment

Measure method:

Oswestry Index rating Scale

指标中文名:

EOS 脊柱全长片检查评估

指标类型:

次要指标

Outcome:

/

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS评估

指标类型:

主要指标

Outcome:

/

Type:

Primary indicator

测量时间点:

治疗前、治疗10天、治疗20天、治疗1个疗程后

测量方法:

vas评估量表

Measure time point of outcome:

Before treatment, 10 days of treatment, 20 days of treatment, 1 course of treatment

Measure method:

Vas scale

指标中文名:

脊柱肌肉组织状态评价

指标类型:

次要指标

Outcome:

/

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

不需要

组织:

Sample Name:

no

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本试验采用组间及组内前后对照研究,按照数字随机法确定入组。

Randomization Procedure (please state who generates the random number sequence and by what method):

In this research, a control study was conducted between groups and within groups, and enrollment was determined by numerical randomization.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

相关研究结果发表3个月后

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Three months after the results were published

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究数据采集:临床数据类型采集就是 CRF 表,CRF表由课题组成员接诊时负责填写,完成后交给项目负责人,最后总结时交给数学统计人员。 研究数据管理:研究所有的数据、原始文档上传至临床试验公共管理平台(http://www.medresman.org.cn/login.aspx)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Research data collection: Clinical data type collection is the CRF form, which is filled in by the members of the research group when receiving treatment, and delivered to the project leader after completion, and finally to the mathematical statisticians when concluding. Institute of research data management: some data, the original documents uploaded to the clinical trials of public management platform (http://www.medresman.org.cn/login.aspx)

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统